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Abstract Megakaryocytes, the platelet precursors, are induced
to di¡erentiate in response to Mpl ligand. Here we report that
stability of the megakaryocyte-speci¢c platelet factor 4 (PF4)
mRNA is substantially augmented in the presence of Mpl li-
gand. This stabilization requires protein synthesis, but the 3P-un-
translated region of PF4 mRNA is not su⁄cient for granting
the e¡ect. This cytokine also signi¢cantly or mildly stabilizes
Mpl receptor or GAPDH mRNAs, respectively, in contrast to
a previously reported lack of e¡ect on P2Y1 receptor mRNA.
Our study is the ¢rst to suggest that Mpl ligand-induced lineage
speci¢cation is also determined by message stabiliza-
tion. 1 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
Key words: Megakaryocyte; Megakaryopoiesis ; mRNA;
Message stability; Mpl ligand
1. Introduction
Megakaryocytes are hematopoietic precursors of platelets,
which play an essential role in thrombosis and hemostasis [1].
Megakaryocyte proliferation, polyploidization and matura-
tion are primarily regulated by the megakaryocyte growth
and development factor (MGDF), also called thrombopoietin,
the ligand of the myeloproliferative (Mpl) receptor [2,3]. Sev-
eral studies have examined the role of Mpl ligand in determin-
ing lineage speci¢city by focusing on transcriptional regula-
tion [4,5]. This route of investigation has necessitated in most
cases the use of cell lines because of the rarity of megakaryo-
cytes in the bone marrow (V0.05% of total mononuclear
cells) and the di⁄culties associated with isolating a su⁄cient
number of primary megakaryocytes for study.
The phenotype and function of a cell are de¢ned by the
spectrum of its cytoplasmic mRNAs. The level of a speci¢c
mRNA is determined by the balance between its rates of syn-
thesis and degradation. Recent studies in a variety of exper-
imental systems highlighted the central role of mRNA stabil-
ity in the abundance of cellular proteins [6]. Among the genes
exclusively expressed in megakaryocytes is the platelet factor 4
(PF4). PF4 is an abundant and stable protein, which was
identi¢ed as a chemokine component of the K-granules, with
potential immunomodulatory and antiangiogenic activity [7].
Hence, the regulation of PF4 mRNA abundance may impact
on the control of such processes as angiogenesis as well as on
lineage determination.
In the current study, we have shown that the steady state
level of PF4 mRNA was increased by 10-fold in the Y10/
L8057 murine megakaryocytic cell line in response to stimu-
lation with Mpl ligand. PF4 promoter activity was increased
only by about two-fold. Message stability, however, was sub-
stantially augmented. Similarly, Mpl ligand considerably aug-
mented Mpl receptor mRNA stability, but signi¢cantly less so
of GAPDH mRNA. Our study is novel as it indicates that
Mpl ligand-induced lineage di¡erentiation is also determined
by mRNA stabilization. Such an increase in message stability
is important in understanding the major burst in protein syn-
thesis seen during the ¢nal phases of megakaryopoiesis.
2. Materials and methods
2.1. Cell culture and materials
The Mpl ligand-responsive Y10 subclone [8] of a murine megakar-
yocytic cell line L8057 [9] was maintained in F12 medium, supple-
mented with 10% fetal bovine serum (FBS), 4 mM L-glutamine, 50 U/
ml penicillin and 50 Wg/ml streptomycin (all Gibco BRL, Gaithers-
burg, MD, USA) in a humidi¢ed incubator at 37‡C with 5% CO2.
Cells were induced to di¡erentiate by growing in Iscove’s modi¢ed
Dulbecco’s medium (IMDM) (Gibco BRL), supplemented as above,
in the presence of 25 ng/ml of a recombinant Mpl ligand (PEG-rHu-
MGDF, generously supplied by Amgen, Thousand Oaks, CA, USA)
as it was shown before to elevate ploidy and lineage-speci¢c markers
[5,8]. 5 Wg/ml of actinomycin D (ActD), 15 mg/ml of 5,6-dichloro-1-L-
D-ribofuranosyl-benzimidazole (DRB), and 100 Wg/ml of cyclohexi-
mide (CHX; all Sigma, St. Louis, MO, USA) were used when indi-
cated.
2.2. Plasmid construction
The plasmids CMV-HGH and CMV-HGH-PF4polyA were con-
structed from fragments of two di¡erent vectors: pcDNA3 (Invitro-
gen, Carlsbad, CA, USA) containing CMV promoter and neomycin-
resistant gene, and pPF4GH containing the rat 1.1-kb PF4 promoter,
linked to the human growth hormone gene (HGH) [10]. pcDNA3 was
linearized with BamHI/EcoRI or BamHI/XbaI restriction digest. The
HGH fragment was excised from pPF4GH vector by BamHI/EcoRI
or BamHI/BglI restriction digest correspondingly. The rat PF4 gene
(GenBank accession number M15254) [11] was used to generate the
rPF4polyA tail by PCR reaction with a pair of speci¢c primers: sense
primer 5P-CTCGAGCCAGGGAGGCACAGAGCCACGCTGAA-
GAATGG-3P and antisense primer 5P-TCTAGAAACATATAAA-
CACTGTGTATTCATTC-3P. This PCR product was ligated to TA
vector (Invitrogen, Carlsbad, CA, USA) and cut with BglI/XbaI re-
striction enzymes. This PF4 3P end spans the region from 640 bp to
1182 bp in the gene (with 0 counted as the transcription start). The
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¢nal plasmids were generated by ligation of gene fragments, which
were puri¢ed using GeneClean II kit (Bio 101, Vista, CA, USA).
Using similar approaches, the PF4 3P-untranslated region (UTR)
was subcloned downstream to the P2Y1 gene (instead of its own
3P end [12]) (GenBank accession number AJ245636).
2.3. mRNA isolation and Northern blot analysis
Total RNA was extracted using TRIzol Reagent (Gibco BRL) ac-
cording to the manufacturer’s instructions. Northern blot analysis was
performed as described elsewhere [13]. As indicated, rat PF4, mouse
Mpl receptor, GAPDH, HGH or 18S cDNAs were used as probes.
The probes, available by cloning or by PCR, were con¢rmed by DNA
sequencing (all sequences are available in GenBank). The data were
quantitated using InstantImager (Packard BioScience Company,
Downers Grove, IL, USA) or Electrophoresis Documentation Anal-
ysis System (Eastman Kodak Company, Rochester, NY, USA) as
indicated.
2.4. Transfections and reporter gene assays
Y10/L8057 cells were stably transfected with PF4GH plasmid [10]
or vehicle plasmid (100 Wg each) by electroporation, along with 20 Wg
of pcDNA3 (Invitrogen, Carlsbad, CA, USA), which encodes neo-
mycin acetyltransferase that confers resistance to neomycin analog
G418, as described elsewhere [5]. Stable clones were selected by cul-
turing in the presence of 400 Wg/ml G418 (Gibco BRL) for 4 weeks.
Resistant cells were used in the HGH expression assay that was per-
formed on the medium of cells cultured in the absence or presence of
25 ng/ml MGDF for indicated times [10]. The level of HGH produced
by cells was determined by HGH kit (Nichols Institute Diagnostics,
San Juan Capistrano, CA, USA), as described by the manufacturer,
and normalized to the total cell number. CMV-HGH and CMV-
HGH-PF4polyA plasmids were stably transfected into Y10/L8057
cells and selected, using the above-described method.
2.5. Nuclei isolation and nuclear run-on assay
Nuclei were prepared from Y10/L8057 cells cultured in the absence
or presence of 25 ng/ml MGDF for 24 h as described elsewhere [14].
Isolated nuclei were frozen in liquid nitrogen in 50 mM Tris, pH 8.3, 5
mM MgCl2, 0.1 mM EDTA, and 40% glycerol in aliquots of 107
nuclei/100 Wl. Nuclear run-on assay was performed essentially as we
described before, with minor modi¢cations [5].
2.6. Analysis of mRNA decay
Y10/L8057 cells were plated at a concentration of 5U105 cells/ml in
IMDM medium with 10% FBS. At the time of seeding, half of the
£asks were supplemented with 25 ng/ml of MGDF. 24 h post seeding,
15 mg/ml of DRB was added to each £ask. At indicated times, after
addition of DRB, cells in each subgroup were harvested for RNA
isolation (TRIzol Reagent, Gibco BRL) and Northern blot analysis
was performed as described above. The same membrane was stripped
by treatment with boiling solution of 0.2% SDS and used for several
probes. For graphic representation of the data, the intensity of the
band for time 0 was referred to as 100%. Control for e⁄cient inhibi-
tion of gene transcription was performed in each experiment by in-
cubating cells in the presence of DRB prior to incubation with
MGDF (data not shown).
3. Results and discussion
3.1. E¡ect of Mpl ligand on PF4 gene expression in
megakaryocytes
It had been previously shown that the Y10/L8057 megakar-
yocytic cell line responds to Mpl ligand through increases in
cell ploidy and abundance of megakaryocytic markers [5,8].
Because of the rarity of megakaryocytes in bone marrow, we
utilized this cell system to explore the mechanisms by which
PF4 mRNA is elevated by the Mpl ligand. The PF4 gene
encodes an extremely abundant protein, which is found only
within K-granules of megakaryocytes and platelets, therefore
serving as an excellent marker of lineage di¡erentiation
[11,15]. The steady state level of PF4 mRNA was elevated
by up to 10-fold by treatment with the recombinant Mpl li-
gand, MGDF (see Section 2) (Fig. 1). To explore the induc-
ibility of the PF4 gene promoter by MGDF, we utilized the
Y10/L8057 cell line, stably transfected with the PF4GH plas-
mid [10] (see Section 2). The PF4 promoter regulatory ele-
ments (P1, P2, and P3), identi¢ed by transfection of rat
bone marrow cells [10], were con¢rmed to act similarly in
Y10/L8057 cells (data not shown). This suggested that the
regulation of the PF4 promoter is similar in the cell line
and primary cells. In our studies, the activity of the PF4
promoter in Y10/L8057 cells was increased only by 1.6-fold
after 24 h of MGDF treatment and by 2.4-fold after 48 h of
treatment (Fig. 2A). In addition, nuclear run-on assay indi-
cated that the rate of transcription of the endogenous PF4
gene was not signi¢cantly changed by MGDF (Fig. 2B). We
recognize, however, that the sensitivity of this assay is too low
to reproducibly detect di¡erences in the range of two-fold.
Based on the results described above, we wished to explore
to what extent mRNA transcription and/or protein synthesis
was required for MGDF e¡ect on the level of PF4 mRNA in
Y10/L8057 cells. As seen in Fig. 3, the blockage of protein
synthesis by the addition of CHX [8] or message transcription
by the treatment with ActD [16] led to abrogation of MGDF
e¡ect on PF4 mRNA. Hence, we concluded that mRNA tran-
scription together with translation was required for the e¡ect
of MGDF on PF4 mRNA.
Fig. 1. The level of PF4 mRNA is increased in response to MGDF
treatment in the megakaryocytic cell line Y10/L8057. A: Northern
blot analysis of PF4 mRNA. Y10/L8057 cells were plated at a con-
centration of 5U105 cells/ml in IMDM medium supplemented with
10% FBS in the presence or absence of 25 ng/ml MGDF. At indi-
cated times, cells were harvested, followed by RNA extraction. To-
tal RNA was electrophoresed, transferred onto a nylon membrane,
and hybridized with a 32P-labeled rat PF4 cDNA. 18S ribosomal
RNA (rRNA) was determined for loading control. B: Quantitative
representation of Northern blot analysis. The data were analyzed by
an InstantImager (Packard BioScience), followed by normalization
to 18S rRNA. The data presented are representative of three experi-
ments performed.
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3.2. PF4 mRNA stability is augmented in Y10/L8057 cells in
response to MGDF
Since MGDF-induced elevation of PF4 promoter activity
was not as high as that of PF4 mRNA, we suspected that this
cytokine might have an e¡ect on PF4 mRNA half-life. To
measure the kinetics of PF4 message decay, we treated Y10/
L8057 cells with the transcriptional inhibitor DRB [17] after
24 h incubation in the presence or absence of MGDF. The
choice of DRB concentration (15 mg/ml) was based on its
e¡ective inhibition of transcription (data not shown) without
compromising cell viability (Fig. 4A, lower panel). As shown
in Fig. 4, treatment of Y10/L8057 cells with MGDF resulted
in a substantial increase in PF4 mRNA half-life (from about
18 h to more than 28 h in the presence of MGDF). The
stability of Mpl receptor mRNA, a selectively abundant mes-
sage, was also enhanced by MGDF (from about 14 h to al-
most 24 h) (Fig. 4). In addition, we have found that Mpl
ligand had a general modest protective e¡ect on mRNAs, as
re£ected by a small increase in GAPDH mRNA stability
(from about 18 h to close to 21 h in the presence of
MGDF; Fig. 4B). In a di¡erent study in the same cell type
we reported that Mpl ligand had no signi¢cant in£uence on
the P2Y1 receptor mRNA [18], which has a half-life of 2^3 h,
indicating a selective e¡ect of this cytokine on mRNA decay
rates. It should be pointed out that the half-life of PF4
mRNA was estimated in the range of 15^18 h when using
the transcription inhibitor ActD (data not shown). This was
not used for detailed studies because of its toxicity during
prolonged incubation.
Sottile et al. reported that human platelets contain large
amounts of PF4 mRNA, suggesting a prolonged half-life for
this message [19]. We, hence, propose that upon lineage de-
termination, Mpl ligand ensures high abundance of PF4
mRNA in di¡erentiating megakaryocytes by a combined ef-
fect on gene transcription and mRNA stability.
3.3. The role of the 3P end of the PF4 gene in conferring
message stability
Stabilities of speci¢c eukaryotic mRNAs can vary markedly
(reviewed in [16,20]). The 5P-UTR and more frequently the
3P-UTR within mRNAs, as well as sequences within a coding
region were shown to contain binding sites for a number of
Fig. 2. Increased PF4 promoter activity in response to MGDF.
A: PF4 promoter activity. Y10/L8057 cells, stably transfected with
PF4GH plasmid, were seeded in six-well plates at a concentration
of 105 cells/ml in IMDM medium supplemented with 10% FBS in
duplicates. At the time of seeding, half of the wells were treated
with 25 ng/ml MGDF. After 10, 24, and 48 h in culture, medium
aliquots were taken to count cell number and to determine the level
of HGH production. HGH concentration was determined by radio-
immunoassay as described in Section 2. The data are averages of
two experiments performed in duplicates. Error bars represent stan-
dard errors. B: Nuclear run-on assay. 10 Wg of plasmid containing
cDNA for PF4, GAPDH, 18S rRNA or pUC 19 was applied to ni-
trocellulose. The data presented are of a representative experiment
out of three performed. Fold induction by MGDF was calculated
with the use of the Electrophoresis Documentation Analysis System
(Eastman Kodak Company, Rochester, NY, USA). The exposure
time for 18S rRNA was 1/5 of the time for the rest of the bands.
Fig. 3. PF4 mRNA is regulated on multiple levels in Y10/L8057
megakaryocytes. A: Northern blot analysis. Y10/L8057 cells were
plated at a concentration of 8U105 cells/ml in IMDM medium sup-
plemented with 10% FBS. At the time of seeding, cells were treated
with 100 Wg/ml CHX or 5 Wg/ml ActD, as indicated, and 30 min
later 25 ng/ml MGDF was added, also as indicated, and the incuba-
tion was continued for 24 h. Next, cells were harvested and RNA
was extracted. Total RNA was electrophoresed, transferred onto a
nylon membrane, and hybridized with a 32P-labeled PF4 cDNA.
18S rRNA probe was determined as a loading control. B: Quantita-
tive representation of Northern blot analysis. The data were ana-
lyzed by an InstantImager (Packard BioScience), followed by nor-
malization to 18S rRNA. The data presented are representative of
two experiments performed.
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RNA-binding proteins, which determine the fate of the tran-
script [20^23]. PolyA sequences have multiple functions a¡ect-
ing nuclear processing of pre-mRNA, transport to the cyto-
plasm, translation, and cytoplasmic mRNA stability. Hence,
we investigated the role of the 3P end of the PF4 gene in
conferring message stability by utilizing chimeric mRNAs.
To this end, we used the HGH gene to generate constructs
for stable transfections into the megakaryocytic Y10/L8057
cell line (Fig. 5A). We wished to examine whether the replace-
ment of the gene’s 3P-UTR with the 3P end of the PF4 gene
would further enhance the stability of HGH message or would
confer the stabilizing e¡ect of MGDF. The 542 bp 3P-UTR of
the PF4 gene, used in our study, contained two polyA sites.
HGH mRNA has a half-life of approximately 9 h [24], as also
con¢rmed in our system. As shown in Fig. 5C, MGDF treat-
ment increased the level of HGH produced in the stably trans-
fected cells. This was not surprising since the expression of
these messages was driven by the CMV promoter, which we
have found before to be activated by Mpl ligand [5]. Never-
theless, the decay rate of HGH mRNA in the presence or
absence of MGDF was comparable (Fig. 5B,C). Similar re-
sults were obtained for an ADP receptor gene P2Y1 chimeric
construct (see Section 2), containing the PF4 3P-UTR (data
not shown). This message has a half-life of about 2.5 h [18].
Thus, the PF4 mRNA 3P-UTR is not su⁄cient for granting
message stability in response to Mpl ligand.
Fig. 4. MGDF treatment of Y10/L8057 cells results in increased stability of PF4 and Mpl receptor mRNAs. Y10/L8057 cells were plated at a
concentration of 5U105 cells/ml in IMDM medium supplemented with 10% FBS, in the presence or absence of 25 ng/ml MGDF. 24 h post
seeding, 15 mg/ml DRB was added to each £ask. At indicated times after DRB treatment, the cells were harvested, followed by RNA extrac-
tion. Total RNA was electrophoresed, transferred onto a nylon membrane, and hybridized with 32P-labeled cDNAs as indicated. A: Graphic
representation of the data. The data were analyzed using an Electrophoresis Documentation Analysis System (Eastman Kodak Company,
Rochester, NY, USA). All data were normalized to 18S rRNA and the intensity of the band for time 0 was used as 100%. Shown are averages
T standard deviations. Since DRB speci¢cally inhibits transcription initiation by RNA polymerase II, the level of 18S rRNA did not decrease
over time and has not been plotted. B: Northern blot analysis of a representative experiment, out of three performed. ‘+’ and ‘3’ each indi-
cates the presence and absence of MGDF. PF4 mRNA band appears as 0.9 kb, GAPDH mRNA as 1.5 kb, Mpl receptor mRNA as 3 kb, and
the 18S rRNA as 1.9 kb. Relative exposure time of the ¢lms is indicated. For each experiment, the probes with 18S cDNA were also subjected
to shorter exposure times to avoid quantitation of saturated bands.
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In summary, we propose that the maintenance of a mega-
karyocytic phenotype partially depends on stabilization of se-
lective mRNAs. Mpl ligand e¡ect on the level of PF4 mRNA
re£ects combined in£uences on gene transcription and mes-
sage stabilization. Although our report is the ¢rst to link
maintenance of a megakaryocyte di¡erentiation phenotype
to mRNA stability, this phenomenon was reported before in
regard to globin mRNAs stabilization and erythropoiesis [25].
As indicated above (Fig. 3), mRNA transcription and protein
synthesis were both required for Mpl ligand e¡ect on the level
of PF4 mRNA in Y10/L8057 cells, indicating that the mech-
anism of PF4 mRNA stabilization involves synthesis of spe-
ci¢c proteins. Future studies should identify common or
unique sequences within a variety of megakaryocyte-selective
mRNAs that are essential for stabilization in response to Mpl
ligand.
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Fig. 5. The role of the 3P-UTR of the PF4 gene on message stability
of HGH. A: Schemes of the HGH constructs used for transfection.
pCMV-HGH consists of 2150 bp of the HGH gene down to the
stop codon, with its native 3P end and polyA signal. pCMV-HGH-
PF4polyA consists of the HGH gene and 542 bp of PF4 3P-UTR
and polyA signal, replacing the native HGH 3P end. The numbers
in the schemes denote bp positions, with 1 being the 5P end of the
CMV promoter. B,C: Y10/L8057 cells, stably transfected with
CMV-HGH or CMV-HGH-PF4polyA plasmids, were used for
mRNA stability determination as described in Fig. 4. B: Graphic
representation of the data. The intensity of the band for time 0 was
used as 100% and data were normalized to 18S rRNA. C: Northern
blot analysis of a representative experiment, out of two performed.
To avoid quantitation of saturated bands the ¢lters were also sub-
jected to a shorter exposure (than the one shown here for the pur-
pose of illustration).
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